MedTrace Logo

Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium Content

NCT02383238 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2018-05-11

No results posted yet for this study

Summary

Dapagliflozin leads to improved vascular function in the micro- and macrocirculation by action on various cardiovascular risk factors, in particular by effectively controlling hyperglycemia, arterial hypertension and reducing whole sodium content amongst others.

Conditions

  • Diabetes Mellitus Type 2

Interventions

DRUG

Dapagliflozin

10 mg, oral for 6 weeks

DRUG

Placebo

oral for 6 weeks

Sponsors & Collaborators

  • University of Erlangen-Nürnberg Medical School

    lead OTHER

Principal Investigators

  • Roland Schmieder, Prof. · Department of Medicine 4, University of Erlangen-Nuernberg

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02383238 on ClinicalTrials.gov